Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05555732 · ClinicalTrials.gov registry record · Phase 3
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
A Phase 3 study of Metastatic Non Small Cell Lung Cancer, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 3
- Development phase
- 1,170
- Enrollment target
- 20
- Study locations
NCT05555732 is a Phase 3 study of Metastatic Non Small Cell Lung Cancer that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 1,170 participants, above the 355-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (230% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT05555732, a Phase 3 study of Metastatic Non Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Datopotamab Deruxtecan
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Cancer Specialist of North Florida - Jacksonville
- Cancer Care Centers of Brevard, Inc. - Palm Bay
- Woodlands Medical Specialists, Pa - Pensacola
- Florida Cancer Specialists-North - St. Petersburg
California
- Hoag Memorial Hospital Prebyterian - Newport Beach
- Compassionate Cancer Care Medical Group - Riverside
- Sansum Clinic - Santa Barbara
- Ronald Reagan UCLA Medical Center - Santa Monica
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute; Inv Drg Svc Pharm - Boston
- Dana Farber Cancer Institute At St. Elizabeth'S Medical Center - Brighton
Arizona
- Ironwood Cancer and Research Centers - Chandler
- Arizona Oncology Associates, Pc - Nahoa - Prescott Valley
Maryland
- American Oncology Partners of Maryland - Bethesda
- Maryland Oncology Heamtology P.A. - Columbia
Alabama
- Southern Cancer Center Pc - Daphne
Colorado
- UCHealth Memorial Hospital - Colorado Springs
Georgia
- Emory University - Winship Cancer Institute Wci - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,170 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2029-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05555732
The ClinicalTrials.gov registry entry for NCT05555732 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 355-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (230% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05555732 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05555732 about?
NCT05555732 is a clinical study titled "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)". This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell l...
What is the current status of trial NCT05555732?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,170 participants. The study started on 2023-01-11. Estimated completion is 2029-05-11.
What conditions does trial NCT05555732 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer.
What interventions are being tested in trial NCT05555732?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Datopotamab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT05555732?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05555732 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RECRUITING · Phase 3
-
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.